RARE DISEASES A–Z · LETTER H
Hemophilia B
Hemophilia B is the second form of classic hemophilia: an inherited deficiency of clotting factor IX rather than factor VIII. It bleeds the same way as hemophilia A — into joints, muscles, and after injury — and is managed by the same haemophilia centres, but it is less common and has some distinct features.
By Dr. Mohamed Ibrahim, MD, PhD — Assistant Professor of Medicine, Transplant Nephrology, University of Maryland School of Medicine · Last reviewed: November 2026
Rare Diseases A–Z is part of the MedicalVideos.com education program. It is produced independently of sponsors, and any future sponsorship will be labelled on the hub.
The guide
The basics
Factor IX works in partnership with factor VIII in the clotting cascade; lacking either produces the same clinical picture, which is why the two hemophilias were only separated in the 1950s. Severity follows the factor IX level: severe (under 1% of normal) causes spontaneous bleeds into joints and muscles from early childhood; moderate (1–5%) bleeds after minor trauma; mild (5–40%) may surface only at surgery or after injury. Repeated joint bleeds progressively damage cartilage and bone. Because it is X-linked, hemophilia B mainly affects males; female carriers usually have adequate levels, but some have levels low enough to cause heavy periods, postpartum bleeding, or surgical bleeding and deserve assessment in their own right. Hemophilia B is roughly five times less common than hemophilia A.
How it works
Blood tests show the same pattern as hemophilia A — a prolonged APTT — and the specific factor IX assay gives the level. Genetic testing of the F9 gene confirms the variant and supports carrier testing; one particular variant causes the unusual 'hemophilia B Leyden' pattern, in which factor levels rise after puberty and symptoms ease. Inhibitors (antibodies against factor IX) are less common than in hemophilia A but can be complicated by allergic reactions to factor IX, so first treatments in children are given where help is at hand. Haemophilia centres also assess joint health, arrange family testing, and check the health consequences of any historical blood-product exposure.
Day to day
Prevention is the standard for severe disease: regular intravenous factor IX keeps levels protective, and because factor IX lasts longer than factor VIII — especially the extended half-life versions — infusions may be needed only every one to two weeks. Gene therapy is a genuine option for eligible adults with hemophilia B: a single infusion delivers a working F9 gene (in one product, a naturally more active variant of factor IX) to liver cells, and most recipients in trials maintained levels that removed the need for prophylaxis. Bleeds are treated promptly with factor IX concentrate. If inhibitors develop, bypassing agents control bleeds, though the antibody-mimic medicine used in hemophilia A does not apply here. Physiotherapy, joint protection, and weight management round out care.
When to get help
Long-term care mirrors hemophilia A: centre-based review, joint surveillance, inhibitor checks, and a treatment record that travels with you. Tell dentists and surgeons early — planned procedures go smoothly when the centre arranges factor cover in advance. Avoid intramuscular injections and clotting-impairing painkillers unless the centre agrees. Head injury, throat swelling, severe abdominal or back pain, or a bleed not responding to home treatment means emergency care. Women who carry the gene should have their factor IX level measured and a delivery plan for pregnancy, since both mother and a potentially affected baby need the centre involved at birth.
Common questions
Why is it called Christmas disease?
Hemophilia B is sometimes called Christmas disease — not for the season, but after Stephen Christmas, the first patient described with the distinct factor IX deficiency in 1952. The name B simply marks it as the second hemophilia type identified.
How is hemophilia B different from hemophilia A in practice?
Clinically they are indistinguishable — same bleeding pattern, same joint damage, same severity bands. They differ in the missing factor (IX versus VIII), in inhibitor frequency (less common in B), and in some treatment details.
Why can factor IX be given less often?
Factor IX naturally lasts longer in the circulation than factor VIII, and engineered extended half-life factor IX products last longer still — many people on prophylaxis manage with an infusion every one to two weeks, a lighter burden than hemophilia A historically required.
Is gene therapy available for hemophilia B?
Yes. Gene therapy for hemophilia B — a one-time infusion that enables the liver to make factor IX — is approved in several countries for eligible adults, and in trials most recipients stopped regular prophylaxis. Suitability depends on liver health, antibodies to the delivery virus, and personal preference.
More in Letter H
Related
Sources
- Hemophilia B (MedlinePlus)
- Hemophilia B (National Organization for Rare Disorders (NORD))
- Hereditary Factor IX Deficiency (Hemophilia B) — Genetic and Rare Diseases Information Center (NIH GARD)
- Hemophilia (CDC)
This guide is general information, not medical advice. Rare diseases are individual — diagnosis and treatment depend on your own results, other conditions, and treatment history, and are set by your treating team. Never start, stop, or change a medicine because of something you read here. If you have severe breathlessness, uncontrolled bleeding, confusion, sudden weakness, or thoughts of harming yourself, seek urgent care. Factor dosing, prophylaxis, and activity advice are individual; follow your haemophilia centre's plan.